What is claimed is:

1. A deuterium enriched compound having the structure:



or a pharmaceutically acceptable salt thereof,
wherein R_1-R_3 are independently H or D, and wherein at least one of R_1-R_3 is deuterium enriched.

2. The deuterium enriched compound ~~of claim 1~~ or ~~a~~ pharmaceutically acceptable salt thereof of claim 1, wherein R_1 is deuterium enriched, and each of R_2 and R_3 is H.

3. The deuterium enriched compound ~~of claim 1~~ or ~~a~~ pharmaceutically acceptable salt thereof of claim 1, wherein R_1 is H, and each of R_2 and R_3 is deuterium enriched.

4. The deuterium enriched compound ~~of claim 1~~ or ~~a~~ pharmaceutically acceptable salt thereof of claim 1, wherein each of R_1, R_2 and R_3 is deuterium enriched.

5. The deuterium enriched compound ~~of any one of claims 1 to 4~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the at least one of R_1-R_3 is deuterium enriched to have an isotopic purity of at least 10%.

6. The deuterium enriched compound ~~of any one of claims 1 to 4~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the at least one of R_1-R_3 is deuterium enriched to have an isotopic purity of at least 50%.

7. The deuterium enriched compound ~~of any one of claims 1 to 4~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the at least one of R_1-R_3 is deuterium enriched to have an isotopic purity of at least 70%.

8. The deuterium enriched compound ~~of any one of claims 1 to 4~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the at least one of R_1-R_3 is deuterium enriched to have an isotopic purity of at least 90%.

9. The deuterium enriched compound ~~of any one of claims 1 to 4~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1 to 4, wherein the at least one of R_1-R_3 is deuterium enriched to have an isotopic purity of at least 95%.

10. The deuterium enriched compound of any one of claims 1 to 9, in the form of free base.

11. The deuterium enriched compound of any one of claims 1 to 9, in the form of a pharmaceutically acceptable salt, wherein the pharmaceutically acceptable salt is selected from the group consisting of citrate, mesylate, maleate, malate, fumarate, tannate, tartrate, esylate, p-toluenesulfonate, benzoate, acetate, phosphate, oxalate and sulfate salts.

12. The deuterium enriched compound of claim 11, in the form of a mesylate salt or a citrate salt.

13. A pharmaceutical composition comprising the deuterium enriched compound ~~of any one of claims 1-12,~~ or ~~a~~ pharmaceutically acceptable salt thereof of any one of claims 1-12, and a pharmaceutically acceptable carrier.

14. A mixture of at least two different deuterium enriched compounds, each compound having the structure:



or pharmaceutically acceptable salts thereof, wherein R_1-R_3 are independently H or deuterium enriched.

15. The mixture of claim 14, wherein at least one of the at least two deuterium enriched compounds has the structure:



or pharmaceutically acceptable salts thereof.

16. The mixture of claim 14, wherein at least one of the at least two deuterium enriched compounds has the structure:



or pharmaceutically acceptable salts thereof.

17. The mixture of claim 14, wherein at least one of the at least two deuterium enriched compounds has the structure:



or pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising the mixture of any one of claims 14-17~~, or a pharmaceutically acceptable salt thereof,~~ and a pharmaceutically acceptable carrier.

19. Use of the deuterium enriched compound or pharmaceutically acceptable salt thereof of any one of claims 1-12, in the manufacture of a medicament for ~~A method of~~ treating a neurodegenerative disorder in a subject in need thereof, wherein the medicament comprises ~~the method comprising periodically administering to the subject in need~~ a therapeutically effective amount of the deuterium enriched compound for periodic administration~~ comprising as an active ingredient the deuterium enriched compound of any one of claims 1-12, or pharmaceutically acceptable salt thereof, thereby to effectively treat the subject~~.

20. The ~~method~~use of claim 19, wherein the therapeutically effective amount of the base form of the deuterium enriched compound is 0.2-2.5 mg per day.

21. The ~~method~~use of claim 20, wherein the therapeutically effective amount of the base form of the deuterium enriched compound is 0.5 mg per day.

22. The ~~method~~use of claim 20, wherein the therapeutically effective amount of the base form of the deuterium enriched compound is 1 mg per day.

23. The ~~method~~use of claim 20, wherein the therapeutically effective amount of the base form of the deuterium enriched compound is 2 mg per day.

24. The ~~method~~use of any one of claims 19-23, wherein the dosage form is an oral dosage form.

25. The ~~method~~use of any one of claims 19-23, wherein the dosage form is a transdermal patch.

26. The ~~method~~use of any one of claims 19-25, wherein the neurodegenerative disorder is selected from the group consisting of Parkinson's disease, Restless Legs Syndrome, Multiple System Atrophy, Progressive Supranuclear Palsy, Glaucoma, Macular Degeneration, Hearing loss, Retinitis Pigmentosa, and Olfactory Dysfunction.

27. The ~~method~~use of claim 26, wherein the neurodegenerative disorder is Parkinson's disease.

28. Use of the deuterium enriched compound or pharmaceutically acceptable salt thereof of any one of claims 1-12, in the manufacture of a medicament for ~~A method of~~ reducing the rate of progression of Parkinson's disease in an early stage Parkinson's disease patient.~~, the method comprising periodically administering to an early stage Parkinson's disease patient an amount of the deuterium enriched compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof, effective to reduce the rate of progression of Parkinson's disease of the early stage Parkinson's disease patient.~~

29. A process for the preparation of a deuterium enriched compound having the structure: